Review ArticleSystematic Review
Open Access

Comorbidities and severity of coronavirus disease 2019 patients

Nashwa M. Radwan, Nagla E. Mahmoud, Amal H. Alfaifi and Khaled I. Alabdulkareem
Saudi Medical Journal November 2020, 41 (11) 1165-1174; DOI: https://doi.org/10.15537/smj.2020.11.25454

References

  1. ↵
    1. Khot WY,
    2. Nadkar MY
    (2020) The 2019 novel coronavirus outbreak-a Global threat. J Assoc Physicians India 68:67–71.
    OpenUrl
    1. Callaway E,
    2. Cyranoski D
    (2020) China coronavirus:six questions scientists are asking. Nature 577:605–607.
    OpenUrlCrossRefPubMed
    1. Phan LT,
    2. Nguyen TV,
    3. Luong QC,
    4. Nguyen TV,
    5. Nguyen HT,
    6. Le HQ,
    7. et al.
    (2020) Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 382:872–874.
    OpenUrlCrossRefPubMed
    1. Rothe C,
    2. Schunk M,
    3. Sothmann P,
    4. Bretzel G,
    5. Froeschl G,
    6. Wallrauch C,
    7. et al.
    (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382:970–971.
    OpenUrlCrossRefPubMed
    1. World Health Organization
    Coronavirus disease (COVID-2019) situation reports-94, [Updte 2020], Available from URL: https://www.who.int/emergencies/diseases/novel. Accessed: 2020 April.
  6. ↵
    1. National Health Commission of the People's Republic of China
    (2020) Updte 2020, Available from URL: http://www.nhc.gov.cn. Accessed: 2020 March.
  7. ↵
    1. Chen N,
    2. Zhou M,
    3. Dong X,
    4. Qu J,
    5. Gong F,
    6. Han Y,
    7. et al.
    (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study. Lancet 395:507–513.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Cui-Cui L,
    2. Xiao-Jia W,
    3. Hwa-Chain RW
    (2019) Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discovery Today 24:726–736.
    OpenUrl
  9. ↵
    1. Emery SL,
    2. Erdman DD,
    3. Bowen MD,
    4. Newton Br,
    5. Winchell JM,
    6. Meyer RF,
    7. Tong S,
    8. et al.
    (2004) Real-Time Reverse Transcription–Polymerase Chain Reaction Assay for SARS-associated Coronavirus. Emerg Infect Dis 10:311–316.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. National Health Commission of China:Diagnosis and treatment of pneumonia caused by novel coronavirus (trial version 5)
    , Update 2020, Available from URL: https://www.chinalawtranslate.com/en/13986-2. Accessed: 2020 February.
  11. ↵
    1. Zhou F,
    2. Yu T,
    3. Du R,
    4. Fan G,
    5. Liu Y,
    6. Liu Z,
    7. et al.
    (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study. Lancet 395:1054–1062.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Guan WJ,
    2. Ni ZY,
    3. Hu Y,
    4. Liang W,
    5. Ou C,
    6. Heet J,
    7. et al.
    (2020) Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med 382:1708–1720.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Huang C,
    2. Wang Y,
    3. Li X,
    4. Ren L,
    5. Zhao J,
    6. Hu Y,
    7. et al.
    (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Liu W,
    2. Tao Z,
    3. Wang L,
    4. Yuan ML,
    5. Liu K,
    6. Zhou L,
    7. et al.
    (2020) Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J 133:1032–1038.
    OpenUrlPubMed
  15. ↵
    1. Zhang JJ,
    2. Dong X,
    3. Cao Yuan YD,
    4. Yang YB,
    5. Yan YQ,
    6. et al.
    (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75:1730–1741.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Wang D,
    2. Hu B,
    3. Hu C,
    4. Zhu F,
    5. Liu X,
    6. Zhang J,
    7. et al.
    (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Cao M,
    2. Zhang D,
    3. Wang Y,
    4. Lu Y,
    5. Zhu X,
    6. Li Y,
    7. Xue H,
    8. Lin Y,
    9. Zhang M,
    10. Sun Y,
    11. Yang Z
    (2020) Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. MedRxiv 395:497–506.
    OpenUrl
  18. ↵
    1. Review Manager (RevMan) [Computer program]. Version 5.3
    (2014) (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen).
  19. ↵
    1. Wells GA,
    2. Shea B,
    3. O'Connell D,
    4. Peterson J,
    5. Welch V,
    6. Losos M,
    7. Tugwell P
    (2019) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses (Ottawa Hospital Research Institute, Ottawa (CN)).
  20. ↵
    1. Guyatt GH,
    2. Oxman AD,
    3. Vist GE,
    4. Kunz R,
    5. Falck-Ytter Y,
    6. Alonso-Coello P,
    7. et al.
    (2008) GRADE:an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924.
    OpenUrlFREE Full Text
  21. ↵
    1. Higgins JPT,
    2. Thompson SG,
    3. Deeks JJ
    (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560.
    OpenUrlFREE Full Text
  22. ↵
    1. Li LQ,
    2. Huang T,
    3. Wang YQ,
    4. Wang ZP,
    5. Liang Y,
    6. Huang TB,
    7. et al.
    (2020) COVID-19 patients'clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 92:577–583.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Vardavas C,
    2. Nikitara K
    (2020) COVID-19 and smoking:A systematic review of the evidence. Tob Induc Dis 18:20.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Wu JT,
    2. Leung K,
    3. Leung GM
    (2020) Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China:a modeling study. Lancet 395:689–697.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Li Q,
    2. Guan X,
    3. Wu P,
    4. Wang X,
    5. Zhou L,
    6. Tong Y,
    7. et al.
    (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199–1207.
    OpenUrlCrossRefPubMed
    1. Tonnesen P,
    2. Marott JL,
    3. Nordestgaard B,
    4. Bojesen SE,
    5. Lange P
    (2019) Secular trends in smoking in relation to prevalent and incident smoking-related disease:A prospective population-based study. Tob Induc Dis 17:72–80.
    OpenUrl
    1. Zhou Z,
    2. Chen P,
    3. Peng H
    (2016) Are healthy smokers really healthy? Tob Induc Dis 14:35–47.
    OpenUrl
  28. ↵
    1. Ladha KS,
    2. Zhao K,
    3. Quraishi SA,
    4. Kurth T,
    5. Eikermann M,
    6. Kaafarani HM,
    7. et al.
    (2015) The Deyo-Charlson and Elixhauser-van Walraven comorbidity indices as predictors of mortality in critically ill patients. BMJ Open 5:9–17.
    OpenUrl
  29. ↵
    1. World Health Organization
    Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), Update 2020 February 14-20, Available from URL: https://www.ncbi.nlm.nih.gov/pubmed/32267833. Accessed: 2020 May.
  30. ↵
    1. Fang L,
    2. Karakiulakis G,
    3. Roth M
    (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8:21–23.
    OpenUrl
  31. ↵
    1. Lippi G,
    2. Wong J,
    3. Henry BM
    (2020) Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19):a pooled analysis. Pol Arch Intern Med 130:304–309.
    OpenUrlPubMed
    1. Wan S,
    2. Xiang Y,
    3. Fang W,
    4. Zheng Y,
    5. Li B,
    6. Hu Y,
    7. et al.
    (2020) Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol 92:797–806.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Zheng YY,
    2. Ma YT,
    3. Zhang JY,
    4. Xie X
    (2020) COVID-19 and the cardiovascular system. Nat Rev Cardiol 17:259–260.
    OpenUrlCrossRefPubMed
  34. ↵
    1. American Diabetes Association
    (homepage on the Internet) Diabetes and Coronavirus. How COVID-19 Impactes People with Diabetes (American Diabetes Association, Arlington) Update 2020; Accessed: 2020 May, Available from URL: https://www.diabetes.org/coronavirus-covid-19/how-coronavirus-impacts-people-with-diabetes.
    1. Wu Z,
    2. McGoogan JM
    (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China:summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239–1242.
    OpenUrlCrossRefPubMed
    1. Onder G,
    2. Rezza G,
    3. Brusaferro S
    (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323:1775–1776.
    OpenUrlPubMed
  37. ↵
    1. International Diabetes Federation
    Diabetes Voice;COVID-19 and diabetes, Update 2020, available from URL: https://diabetesvoice.org/en/news/covid-19-and-diabetes. Accessed: 2020 March.
  38. ↵
    1. Apocella M,
    2. Campopiano M,
    3. Mantuano M,
    4. Mazoni L,
    5. Coppelli A
    (2020) COVID-19 in people with diabetes:understanding the reasons for worse outcome. The Lancet 8:782–792.
    OpenUrl
  39. ↵
    1. Bhutani M,
    2. Hernandez P,
    3. Bourbeau J,
    4. Dechman G,
    5. Penz E,
    6. Aceron Raymond,
    7. et al.
    (2020) Addressing therapeutic questions to help Canadian health care professionals optimize COPD management for their patients during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 4:77–80.
    OpenUrl
  40. ↵
    1. Kim ES,
    2. Bum SI,
    3. Chin BS,
    4. Kang CK,
    5. Kim NJ,
    6. Kang YM,
    7. et al.
    (2020) Clinical course and outcomes of patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection:a Preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci 35:142–154.
    OpenUrl
  41. ↵
    1. Lippi G,
    2. Henry BM
    (2020) Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med 167:105941.
    OpenUrlPubMed
  42. ↵
    1. Zhao Q,
    2. Meng M,
    3. Kumar R,
    4. Wu Y,
    5. Huang J,
    6. Lian N,
    7. et al.
    (2020) The impact of COPD and smoking history on the severity of COVID-19:A systemic review and meta-analysis. J Med Virol 4:1–7.
    OpenUrl
  43. ↵
    1. Wan Y,
    2. Shang J,
    3. Graham R,
    4. Baric RS,
    5. Li F
    (2020) Receptor recognition by novel coronavirus from Wuhan:An analysis based on decade-long structural studies of SARS. J Med Virol 94:120–127.
    OpenUrl
  44. ↵
    1. Restrepo MI,
    2. Mortensen EM,
    3. Pugh JA,
    4. Anzueto A
    (2006) COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 28:346–351.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Cheng Y,
    2. Luo R,
    3. Wang K,
    4. Zhang M,
    5. Wang Z,
    6. Dong L,
    7. et al.
    (2020) Kidney disease is associated with in-hospital death of patients with COVID-19 Yichun. Kidney Int 97:829–38.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Naicker S,
    2. Yang CW,
    3. Hwang SJ,
    4. Liu BC,
    5. Chen JH,
    6. Vivekanand JH
    (2020) The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int 97:824–828.
    OpenUrlPubMed
  47. ↵
    1. Liang W,
    2. Guan W,
    3. Chen R,
    4. Wang W,
    5. Li J,
    6. Xu K,
    7. et al.
    (2020) Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China. Lancet Oncol 21:335–337.
    OpenUrlCrossRefPubMed
  48. ↵
    1. William K
    (2020) COVID-19 infection in cancer patients:early observations and unanswered questions. Ann Oncol 31:838–839.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords